Axsome Therapeutics Inc

NASDAQ:AXSM  
44.64
+0.49 (+1.11%)
Products

Axsome Therapeutics Announces FDA Approval Of Auvelity, For The Treatment Of Major Depressive Disorder In Adults

Published: 08/19/2022 10:55 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces FDA Approval of Auvelity™, the First and Only Oral Nmda Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults.
Axsome Therapeutics Inc - Anticipates Auvelity to Be Commercially Available in U.S. in Q4 of 2022.